Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05430113 · ClinicalTrials.gov registry record · NA
Spinal Cord Stimulation in Spinal Muscular Atrophy
A NA study of Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type 4, sponsored by Marco Capogrosso.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT05430113: Completed NA study of Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type 4, sponsored by Marco Capogrosso.
NCT05430113 is a NA study of Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type 4 that has completed, run by Marco Capogrosso. The registered enrollment target is 3 participants, below the 95-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05430113, a NA study of Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type 4, has completed, sponsored by Marco Capogrosso.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with type 3 or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 3 or 4 SMA aged 16 or older that show quantifiable motor deficits of the legs but are able to stand independently. The investigators will then implant the subjects with percutaneous, bilateral, linear spinal leads near the lumbar spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.
Primary Outcome
Isometric torque: measure the isometric torque produced by the subject at the hip during hip-flexion. Comparison of SCS-on with SCS-off performance. Success Criteria: ≥20% increased torque production over SCS-off baseline as measured during single-joint isometric torque.
Conditions Studied
Interventions
- DEVICE Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-01-13 |
| Phase | NA |
What the finished NCT05430113 record still lists
NCT05430113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 95-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Spinal Muscular Atrophy Type 3 appearing as the primary indexed condition, and to 1 intervention - of which Spinal Cord Stimulator (octopolar Medtronic Vectris Leads) is the first listed.
NCT05430113 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05430113 about?
NCT05430113 is a clinical study titled "Spinal Cord Stimulation in Spinal Muscular Atrophy". Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor d...
What is the current status of trial NCT05430113?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2022-04-05. Estimated completion is 2025-01-13.
What conditions does trial NCT05430113 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 4.
What interventions are being tested in trial NCT05430113?
The interventions under investigation include: Spinal Cord Stimulator (octopolar Medtronic Vectris Leads) (DEVICE).
Who is sponsoring clinical trial NCT05430113?
This trial is sponsored by Marco Capogrosso, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05430113 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05430113's enrollment target sits among peer trials
3 9th of 9 the lowest of 9 other Spinal Muscular Atrophy Type 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Muscular Atrophy Type 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
ACTIVE NOT RECRUITING · NA
-
Gait and Bone Health in SMA
RECRUITING
-
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
RECRUITING
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Spinraza in Adult Spinal Muscular Atrophy
ACTIVE NOT RECRUITING
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI